跳至主要内容
临床试验/NCT01366482
NCT01366482已完成不适用

Directional AthErectomy Followed by a PaclItaxel-Coated BallooN to InhibiT RestenosIs and Maintain Vessel PatEncy: A Pilot Study of Anti-Restenosis Treatment

Medtronic Endovascular1 个研究点 分布在 1 个国家目标入组 121 人开始时间: 2011年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
121
试验地点
1
主要终点
Target Lesion Percent Stenosis

研究概览

简要总结

The DEFINITIVE AR study is a prospective, multi-center, randomized pilot study evaluating the use of either the TurboHawk™ or SilverHawk® plaque excision systems followed by treatment with the Cotavance™ drug-eluting balloon catheter versus the Cotavance balloon catheter alone in patients with peripheral arterial disease.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Rutherford Clinical Category 2-4
  • At least 18 years of age
  • Is able and willing to provide written informed consent prior to study specific procedures

排除标准

  • Has a life expectancy of less than 24 months
  • Is pregnant, of childbearing potential not taking adequate contraceptive measures, or nursing
  • Has one or more of the contraindications listed in the SilverHawk/ TurboHawk or Cotavance IFUs

结局指标

主要结局

Target Lesion Percent Stenosis

时间窗: 1 year

次要结局

未报告次要终点

研究者

发起方
Medtronic Endovascular
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验